Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2019 4
2020 11
2021 7
2022 7
2023 11
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Heterogeneity and treatment landscape of ovarian carcinoma.
Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, Sneha S, Oza AM. Veneziani AC, et al. Among authors: madariaga a. Nat Rev Clin Oncol. 2023 Dec;20(12):820-842. doi: 10.1038/s41571-023-00819-1. Epub 2023 Oct 2. Nat Rev Clin Oncol. 2023. PMID: 37783747 Review.
Mirvetuximab soravtansine: an oasis in the desert?
Bonilla L, Kasherman L, Manso L, Madariaga A. Bonilla L, et al. Among authors: madariaga a. Int J Gynecol Cancer. 2024 Apr 1;34(4):478-479. doi: 10.1136/ijgc-2024-005400. Int J Gynecol Cancer. 2024. PMID: 38388176 No abstract available.
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Madariaga A, Garg S, Tchrakian N, Dhani NC, Jimenez W, Welch S, MacKay H, Ethier JL, Gilbert L, Li X, Rodriguez A, Chan L, Bowering V, Clarke B, Zhang T, King I, Downs G, Stockley T, Wang L, Udagani S, Oza AM, Lheureux S. Madariaga A, et al. Nat Commun. 2023 Mar 15;14(1):1452. doi: 10.1038/s41467-023-37084-w. Nat Commun. 2023. PMID: 36922497 Free PMC article. Clinical Trial.
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Lheureux S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, Bruce JP, Wong D, Danesh A, Torti D, Torchia J, Fortuna A, Singh S, Irving M, Marsh K, Lam B, Speers V, Yosifova A, Oaknin A, Madariaga A, Dhani NC, Bowering V, Oza AM, Pugh TJ. Lheureux S, et al. Among authors: madariaga a. Clin Cancer Res. 2023 Sep 15;29(18):3706-3716. doi: 10.1158/1078-0432.CCR-23-0797. Clin Cancer Res. 2023. PMID: 37327320 Free PMC article. Clinical Trial.
New approaches for targeting platinum-resistant ovarian cancer.
McMullen M, Madariaga A, Lheureux S. McMullen M, et al. Among authors: madariaga a. Semin Cancer Biol. 2021 Dec;77:167-181. doi: 10.1016/j.semcancer.2020.08.013. Epub 2020 Aug 29. Semin Cancer Biol. 2021. PMID: 32871277 Review.
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer.
Marastoni S, Madariaga A, Pesic A, Nair SN, Li ZJ, Shalev Z, Ketela T, Colombo I, Mandilaras V, Cabanero M, Bruce JP, Li X, Garg S, Wang L, Chen EX, Gill S, Dhani NC, Zhang W, Pintilie M, Bowering V, Koritzinsky M, Rottapel R, Wouters BG, Oza AM, Joshua AM, Lheureux S. Marastoni S, et al. Among authors: madariaga a. Cancer Res Commun. 2022 May 4;2(5):293-306. doi: 10.1158/2767-9764.CRC-22-0037. eCollection 2022 May. Cancer Res Commun. 2022. PMID: 36875717 Free PMC article.
45 results